SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced that it is presenting preclinical data at the 19th International Congress on Anti-Cancer Agents, being held February 5-8 in Paris, France, further demonstrating that the Company’s lead cancer compound, APOPTONE™ (HE3235), directly induces apoptosis, or cell death, in tumor cells. Hollis-Eden intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) this month to initiate a Phase I/II clinical trial in late-stage prostate cancer patients.
